Eli Lilly and Company (LLY)
After hours:
| Previous Close | 569.64 |
| Open | 567.19 |
| Bid | 0.00 x 900 |
| Ask | 0.00 x 900 |
| Day's Range | 542.50 - 568.00 |
| 52 Week Range | 304.88 - 601.84 |
| Volume | |
| Avg. Volume | 2,908,842 |
| Market Cap | 522.236B |
| Beta (5Y Monthly) | 0.32 |
| PE Ratio (TTM) | 76.62 |
| EPS (TTM) | 7.18 |
| Earnings Date | Nov 02, 2023 |
| Forward Dividend & Yield | 4.52 (0.79%) |
| Ex-Dividend Date | Aug 14, 2023 |
| 1y Target Est | 569.28 |
ZacksTop Research Reports for Eli Lilly, Toyota Motor, Accenture & Others
Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), Toyota Motor Corporation (TM) and Accenture plc (ACN).
- Investing.com
Obesity treatment optimism boosts Eli Lilly, Novo Nordisk while others face downturn
Pharmaceutical majors Eli Lilly (NYSE:LLY) and Novo Nordisk (NYSE:NVO) have experienced a significant increase in their market value on Thursday, driven by the potential of their weight-loss drugs, GLP-1s, to address the global obesity epidemic. This optimism has propelled sales forecasts into the hundreds of billions. However, this same optimism has negatively impacted companies that have traditionally profited from treating obesity-related complications.
- Investing.com
Obesity drugs by Novo Nordisk and Eli Lilly to impact healthcare economy
Leading pharmaceutical companies, Novo Nordisk (NYSE:NVO) and Eli Lilly (NYSE:LLY), are anticipated to see significant revenue growth from their newly developed obesity drugs, according to financial analysts' predictions. These medications, known as GLP-1 receptor agonists, are considered the safest and most effective weight-loss drugs currently available. They offer potential body weight reductions of up to 20% and could also diminish patients' risk of heart attack or stroke.
